{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:16:40Z","timestamp":1784557000903,"version":"3.55.0"},"reference-count":30,"publisher":"Bioscientifica","content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,7,1]]},"abstract":"Summary<\/jats:title>\n Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused primarily by benign mesenchymal tumors. These tumors typically follow a benign clinical course and local recurrence occurs in <5% of cases. We investigated a 49-year-old man with a recurrent mesenchymal phosphaturic tumor showing no signs of malignancy. The patient suffered from chronic muscle weakness, myalgia and cramps. His medical record included the diagnosis of oncogenic osteomalacia, for which he was submitted to tumor resection in the left leg three times before. Laboratory examination showed hypophosphatemia, hyperphosphaturia and an elevated serum FGF23 level. A radical surgical approach (amputation) was advised, however, complete biochemical and clinical remission was not reached. Molecular analysis of the tumor cells demonstrated overexpression of growth factor receptors implicated in tumor angiogenesis and metastatic potential (platelet derived growth factor type A (PDGFRA), PDGFRB and vascular endothelial growth factor receptor) together with increased expression of FGF23, x-linked-phosphate-regulating endopeptidase and KLOTHO. TIO is usually associated with benign phosphauturic tumors and, when identified, resection of the tumor leads to complete remission in the majority of cases. The underlying pathophysiology of recurrences in these tumors is not known. This is the first report showing increased expression of growth factor receptors in a locally aggressive but histopathologically benign phosphaturic mesenchymal tumor.<\/jats:p>\n \n Learning points<\/jats:title>\n \n \n \n TIO is usually associated with benign soft tissue or bone neoplasms of mesenchymal origin.<\/jats:p>\n <\/jats:list-item>\n \n These tumors typically follow a benign clinical course and even in the rare malignant cases local recurrence occurs in <5%.<\/jats:p>\n <\/jats:list-item>\n \n Successful identification and removal of the tumor leads to full recovery in the majority of cases.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1530\/edm-15-0025","type":"journal-article","created":{"date-parts":[[2015,7,2]],"date-time":"2015-07-02T06:46:24Z","timestamp":1435819584000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":5,"title":["Tumor-induced osteomalacia due to a recurrent mesenchymal tumor overexpressing several growth factor receptors"],"prefix":"10.1530","volume":"2015","author":[{"given":"Maria P","family":"Yavropoulou","sequence":"first","affiliation":[{"name":"Division of Clinical and Molecular Endocrinology, 1st Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, 1 Stilponos, Kyriakidi Street, Thessaloniki, 54636, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolina","family":"Gerothanasi","sequence":"additional","affiliation":[{"name":"Division of Clinical and Molecular Endocrinology, 1st Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, 1 Stilponos, Kyriakidi Street, Thessaloniki, 54636, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Frydas","sequence":"additional","affiliation":[{"name":"Division of Clinical and Molecular Endocrinology, 1st Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, 1 Stilponos, Kyriakidi Street, Thessaloniki, 54636, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Triantafyllou","sequence":"additional","affiliation":[{"name":"Division of Clinical and Molecular Endocrinology, 1st Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, 1 Stilponos, Kyriakidi Street, Thessaloniki, 54636, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Poulios","sequence":"additional","affiliation":[{"name":"1 Pathology Department, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prodromos","family":"Hytiroglou","sequence":"additional","affiliation":[{"name":"1 Pathology Department, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Apostolou","sequence":"additional","affiliation":[{"name":"2 Research Genetic Cancer Centre Ltd (RGCC Ltd), Florina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Papasotiriou","sequence":"additional","affiliation":[{"name":"2 Research Genetic Cancer Centre Ltd (RGCC Ltd), Florina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Symeon","family":"Tournis","sequence":"additional","affiliation":[{"name":"3 Laboratory of Research of Musculoskeletal System \u2018Th. Garofalidis\u2019, Medical School, KAT Hospital, University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaak","family":"Kesisoglou","sequence":"additional","affiliation":[{"name":"4 3rd Department of Surgery, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G","family":"Yovos","sequence":"additional","affiliation":[{"name":"Division of Clinical and Molecular Endocrinology, 1st Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, 1 Stilponos, Kyriakidi Street, Thessaloniki, 54636, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"ref11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/TEN.0b013e3181514e2b","article-title":"Autonomous hyperparathyroidism following long-term phosphate treatment for tumor-induced osteomalacia. Case report and review of the literature","volume":"17","year":"2007","journal-title":"Endocrinologist"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/TEN.0b013e3181514e2b","article-title":"Autonomous hyperparathyroidism following long-term phosphate treatment for tumor-induced osteomalacia. Case report and review of the literature","volume":"17","year":"2007","journal-title":"Endocrinologist"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.surg.2012.08.062","article-title":"Tumor-induced osteomalacia masking primary hyperparathyroidism","volume":"152","year":"2012","journal-title":"Surgery"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"ref151","first-page":"9","article-title":"Tumor-induced hypophosphatemic osteomalacia associated with tertiary hyperparathyroidism: a case report","volume":"27","year":"2006","journal-title":"Il Giornale di Chirurgia"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1210\/jc.2014-2120","article-title":"Ovarian cancer-related hypophosphatemic osteomalacia-a case report","volume":"99","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/jbmr.1642","article-title":"Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature","volume":"27","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1210\/jc.2014-2120","article-title":"Ovarian cancer-related hypophosphatemic osteomalacia-a case report","volume":"99","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref01","first-page":"9","article-title":"Tumor-induced hypophosphatemic osteomalacia associated with tertiary hyperparathyroidism: a case report","volume":"27","year":"2006","journal-title":"Il Giornale di Chirurgia"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1359\/jbmr.2002.17.6.1102","article-title":"Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism","volume":"17","year":"2002","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","article-title":"Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature","volume":"28","year":"2004","journal-title":"American Journal of Surgical Pathology"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","article-title":"Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature","volume":"28","year":"2004","journal-title":"American Journal of Surgical Pathology"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/jbmr.1642","article-title":"Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature","volume":"27","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1359\/jbmr.2002.17.6.1102","article-title":"Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism","volume":"17","year":"2002","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00018-005-5426-3","article-title":"The role of VEGF receptors in angiogenesis; complex partnerships","volume":"63","year":"2006","journal-title":"Cellular and Molecular Life Sciences"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00018-005-5426-3","article-title":"The role of VEGF receptors in angiogenesis; complex partnerships","volume":"63","year":"2006","journal-title":"Cellular and Molecular Life Sciences"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ajh.20778","article-title":"Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response","volume":"82","year":"2007","journal-title":"American Journal of Hematology"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1083\/jcb.200803024","article-title":"FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis","volume":"182","year":"2008","journal-title":"Journal of Cell Biology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4158\/EP11177.CR","article-title":"of tumor - induced osteomalacia and primary hyperparathyroidism","volume":"17","year":"2011","journal-title":"Coexistence Endocrine Practice"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s13277-011-0212-3","article-title":"PDGF: the nuts and bolts of signalling toolbox","volume":"32","year":"2011","journal-title":"Tumour Biology"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1006\/bbrc.2001.5084","article-title":"FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate","volume":"284","year":"2001","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1083\/jcb.200803024","article-title":"FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis","volume":"182","year":"2008","journal-title":"Journal of Cell Biology"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s13277-011-0212-3","article-title":"PDGF: the nuts and bolts of signalling toolbox","volume":"32","year":"2011","journal-title":"Tumour Biology"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.surg.2012.08.062","article-title":"Tumor-induced osteomalacia masking primary hyperparathyroidism","volume":"152","year":"2012","journal-title":"Surgery"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ajh.20778","article-title":"Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response","volume":"82","year":"2007","journal-title":"American Journal of Hematology"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1006\/bbrc.2001.5084","article-title":"FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate","volume":"284","year":"2001","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"ref181","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4158\/EP11177.CR","article-title":"of tumor - induced osteomalacia and primary hyperparathyroidism","volume":"17","year":"2011","journal-title":"Coexistence Endocrine Practice"}],"container-title":["Endocrinology, Diabetes & Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2015\/1\/EDM15-0025.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2015\/1\/EDM15-0025.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:46:04Z","timestamp":1784555164000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,1]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1530\/edm-15-0025","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,1]]}}}